Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mg
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Insomnia
Conditions
Primary Insomnia
Trial Timeline
Sep 1, 2008 → May 1, 2010
NCT ID
NCT00770510About Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mg
Eszopiclone 1 mg + Eszopiclone 2 mg + Eszopiclone 3 mg + Placebo + Zolpidem Tartrate 10 mg is a phase 2/3 stage product being developed by Eisai for Primary Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00770510. Target conditions include Primary Insomnia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00770510 | Phase 2/3 | Completed |
Competing Products
20 competing products in Primary Insomnia